Navigation Links
More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy
Date:4/7/2008

e effects such as retrograde ejaculation, decreased libido, and hypotension as well as patients' belief that symptoms will go away on their own are key reasons for the low drug-treatment rate.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithm Insight Series provide the following:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field.

-- Qualitative diagnosis/referral/treatment algorithm for the United

States.

-- Drug usage by lines of therapy (1st, 2nd, 3rd line).

-- Discussion of key freeform combinations by lines of therapy.

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line).

-- Progression of therapy from key 1st line products.

-- Pathway to key therapies from previous therapies.

-- Qualitative analysis of two-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

78
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
5. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
10. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
11. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Corporation (Nasdaq: DNDN ) announced today that ... have exercised in full their option to purchase ... the public offering price of $24.75 per share. ... size of the offering to an aggregate of ... to receive net proceeds from the offering of ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
(Date:12/10/2009)... (Nasdaq: DNDN ) announced today that it has ... its common stock at a price to the public ... the underwriters a 30-day option to purchase up to ... overallotments, if any. The offering is expected to ... conditions. ,, J. P. Morgan Securities Inc. and Deutsche ...
(Date:12/10/2009)... NEWCASTLE, United Kingdom, Dec. 10 ... North East England Stem Cell Institute (NESCI) ... first successful treatment of eight patients with ... patients, own stem cells without the need ... http://www.newscom.com/cgi-bin/prnh/20080422/CLTU133LOGO-a ) ,, LSCD is a ...
Breaking Biology Technology:Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4
(Date:12/11/2009)... studying how bacteria under stress collectively weigh and initiate ... into how humans make strategic decisions that affect their ... , Their study, published this week in the early ... National Academy of Sciences , was accomplished when the ... describe the complex interplay of genes and proteins that ...
(Date:12/11/2009)... an associate professor of anthropology at the University of ... Kenya to understand how violence shapes the health of ... of her and her colleagues, research," Documenting the health ... northern Kenya: A conceptual framework," is currently published in ... , in collaboration with the British medical journal the ...
(Date:12/11/2009)... Arno Motulsky, the senior editor of the 4th edition ... Human Genetics, was recently given the Victor A. McKusick ... contributions to the field of human genetics, was presented ... American Society of Human Genetics on 24 October 2009 ... Medicine and Genome Sciences at the University of Washington ...
Breaking Biology News(10 mins):Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5UA-led study grapples with health effects of low-intensity warfare 2Mapping the Link Between Alcohol Cancer 60159 1Mapping the Link Between Alcohol Cancer 60159 2Ziosoft Announces Agreement with Imaging 26amp 3B Medical Information Technology to Distribute Ziosoft 26apos 3Bs 3D Advanced Visualization Software 60157 1Ziosoft Announces Agreement with Imaging 26amp 3B Medical Information Technology to Distribute Ziosoft 26apos 3Bs 3D Advanced Visualization Software 60157 2Ziosoft Announces Agreement with Imaging 26amp 3B Medical Information Technology to Distribute Ziosoft 26apos 3Bs 3D Advanced Visualization Software 60157 3Dr Lawrence Brown Named President of the Child Neurology Foundation 60155 1Dr Lawrence Brown Named President of the Child Neurology Foundation 60155 2
... WALNUT CREEK, Calif. The U.S. Department of Energy Joint ... assembly of the soybean (Glycine max) genetic code, making ... new breeding strategies for one of the world,s most ... 70 percent of the world,s edible protein, but also ...
... 8, 2008 Animal feeding operations are an important ... carbon dioxideknown greenhouse gases. Recent inventories suggest that ... methane emissions. As a consequence, greenhouse gas emissions ... development and sustainability of animal production and technologies ...
... help clear the plaques in the brain associated with Alzheimer,s ... The plaques are known to lead to the progressive death ... of dementia. , Sodium valproate - which is marketed as ... at the University of Leeds to reactivate the body,s own ...
Other Biology News:DOE Joint Genome Institute completes soybean genome 2DOE Joint Genome Institute completes soybean genome 3Oil spray reduces greenhouse gas emissions from pig finishing barns 2Epilepsy drug shows potential for Alzheimer's treatment 2
Request Info...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Request Info...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Biology Products: